Merck Income from Continuous Operations 2010-2024 | MRK
Merck annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Merck income from continuous operations for the quarter ending September 30, 2024 was $3.161B, a 33.45% decline year-over-year.
- Merck income from continuous operations for the twelve months ending September 30, 2024 was $12.163B, a 163.27% increase year-over-year.
- Merck annual income from continuous operations for 2023 was $0.377B, a 97.4% decline from 2022.
- Merck annual income from continuous operations for 2022 was $14.526B, a 17.54% increase from 2021.
- Merck annual income from continuous operations for 2021 was $12.358B, a 173.23% increase from 2020.
Merck Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$377 |
| 2022 |
$14,526 |
| 2021 |
$12,358 |
| 2020 |
$4,523 |
| 2019 |
$5,606 |
| 2018 |
$6,193 |
| 2017 |
$2,418 |
| 2016 |
$3,941 |
| 2015 |
$4,459 |
| 2014 |
$11,934 |
| 2013 |
$4,517 |
| 2012 |
$6,299 |
| 2011 |
$6,392 |
| 2010 |
$982 |
| 2009 |
$13,022 |
Merck Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$3,161 |
| 2024-06-30 |
$5,461 |
| 2024-03-31 |
$4,767 |
| 2023-12-31 |
$-1,226 |
| 2023-09-30 |
$4,750 |
| 2023-06-30 |
$-5,972 |
| 2023-03-31 |
$2,825 |
| 2022-12-31 |
$3,017 |
| 2022-09-30 |
$3,253 |
| 2022-06-30 |
$3,949 |
| 2022-03-31 |
$4,307 |
| 2021-12-31 |
$3,824 |
| 2021-09-30 |
$4,571 |
| 2021-06-30 |
$1,214 |
| 2021-03-31 |
$2,749 |
| 2020-12-31 |
$-3,367 |
| 2020-09-30 |
$2,326 |
| 2020-06-30 |
$2,345 |
| 2020-03-31 |
$3,219 |
| 2019-12-31 |
$-1,807 |
| 2019-09-30 |
$1,907 |
| 2019-06-30 |
$2,644 |
| 2019-03-31 |
$2,862 |
| 2018-12-31 |
$1,778 |
| 2018-09-30 |
$1,958 |
| 2018-06-30 |
$1,716 |
| 2018-03-31 |
$741 |
| 2017-12-31 |
$-1,038 |
| 2017-09-30 |
$-51 |
| 2017-06-30 |
$1,951 |
| 2017-03-31 |
$1,556 |
| 2016-12-31 |
$-586 |
| 2016-09-30 |
$2,188 |
| 2016-06-30 |
$1,209 |
| 2016-03-31 |
$1,130 |
| 2015-12-31 |
$982 |
| 2015-09-30 |
$1,831 |
| 2015-06-30 |
$688 |
| 2015-03-31 |
$958 |
| 2014-12-31 |
$7,328 |
| 2014-09-30 |
$842 |
| 2014-06-30 |
$2,033 |
| 2014-03-31 |
$1,731 |
| 2013-12-31 |
$816 |
| 2013-09-30 |
$1,150 |
| 2013-06-30 |
$935 |
| 2013-03-31 |
$1,616 |
| 2012-12-31 |
$949 |
| 2012-09-30 |
$1,763 |
| 2012-06-30 |
$1,820 |
| 2012-03-31 |
$1,767 |
| 2011-12-31 |
$1,543 |
| 2011-09-30 |
$1,724 |
| 2011-06-30 |
$2,054 |
| 2011-03-31 |
$1,071 |
| 2010-12-31 |
$-500 |
| 2010-09-30 |
$372 |
| 2010-06-30 |
$780 |
| 2010-03-31 |
$330 |
| 2009-12-31 |
$6,523 |
| 2009-09-30 |
$3,455 |
| 2009-06-30 |
$1,588 |
| 2009-03-31 |
$1,456 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$260.350B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
